Quince Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Quince Therapeutics kazanç ve gelirinin sırasıyla yıllık 63.6% ve 53% oranında artması tahmin edilirken, EPS'nin yıllık 62.9% oranında büyümesi bekleniyor.

Anahtar bilgiler

63.6%

Kazanç büyüme oranı

62.89%

EPS büyüme oranı

Biotechs kazanç büyümesi	25.3%
Gelir büyüme oranı	53.0%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	06 May 2026

Gelecekteki son büyüme güncellemeleri

Recent updates

Analiz Makalesi • Jan 21

Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...

Seeking Alpha • Jan 12

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Summary Quince Therapeutics is rated Buy ahead of its pivotal Phase 3 NEAT trial readout in Ataxia-Telangiectasia (A-T) expected mid-Q1 2026. eDSP, QNCX's lead asset, offers chronic corticosteroid delivery with reduced toxicity, targeting a $1B+ orphan market with no approved therapies. The NEAT trial addresses prior design flaws, is 90% powered for statistical significance in 6-9 year-olds, and enjoys strong regulatory alignment. QNCX has sufficient cash through the NEAT readout, plans for platform expansion, and has a commercialization partnership with Option Care Health. Read the full article on Seeking Alpha

Analiz Makalesi • Oct 07

Is Quince Therapeutics (NASDAQ:QNCX) Using Too Much Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Seeking Alpha • Aug 20

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Summary Quince’s transformation is complete with the acquisition of EryDel in October 2023. The ongoing Phase 3 trial for the orphan disease Ataxia-Telangiectasia builds on the recently published teachings of EryDel’s earlier trial. Chances for success are high, with approval and multi-billion dollar potential around the corner after topline data next year. The company’s current market cap represents less than half the company’s cash level. Read the full article on Seeking Alpha

Analiz Makalesi • Nov 21

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Seeking Alpha • Jul 27

Cortexyme to change name and ticker symbol next month

Alzheimer’s drug developer Cortexyme (NASDAQ:CRTX) announced on Wednesday that the company would change its corporate name and ticker symbol with effect from August. Accordingly, Cortexyme (CRTX) will be branded as Quince Therapeutics next month, and its ticker symbol on the Nasdaq Global Select Market will change to “QNCX” at the market open on Aug. 01. Coinciding with the change, Quince Therapeutics is expected to issue a press release detailing its growth strategy and plans for the development pipeline. In addition, Quince’s new corporate website and social media profiles on Twitter and LinkedIn will launch on the same day. Seeking Alpha contributor Terry Chrisomalis points out that San Francisco, California-based biotech is pursuing a market opportunity worth $17.7B with its Alzheimer's candidate COR588.

Seeking Alpha • Mar 01

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

COR588 is the second-generation lysine gingipain inhibitor which is being developed to treat Alzheimer's Disease and other P. gingivalis diseases. COR388, the first-generation lysine gingipain inhibitor, didn't achieve statistical significance in the entire Alzheimer's population, but did well in a prespecified group of patients with P. gingivalis. The global market opportunity for Alzheimer's Disease could reach $17.7 billion by 2025. COR388 is not being used towards Alzheimer's Disease, but Cortexyme is still developing it against other P. gingivalis diseases like periodontal disease and oral/head and neck squamous cell carcinoma.

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:QNCX - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2028	51	2	N/A	N/A	2
12/31/2027	26	-22	N/A	N/A	2
12/31/2026	N/A	-33	N/A	N/A	3
3/31/2026	N/A	-33	-40	-39	N/A
12/31/2025	N/A	-84	-42	-41	N/A
9/30/2025	N/A	-57	-39	-38	N/A
6/30/2025	N/A	-49	-36	-36	N/A
3/31/2025	N/A	-61	-34	-33	N/A
12/31/2024	N/A	-57	-32	-32	N/A
9/30/2024	N/A	-53	-31	-30	N/A
6/30/2024	N/A	-53	-28	-28	N/A
3/31/2024	N/A	-30	-23	-23	N/A
12/31/2023	N/A	-31	-18	-18	N/A
9/30/2023	N/A	-28	-18	-18	N/A
6/30/2023	N/A	-31	-20	-20	N/A
3/31/2023	N/A	-42	-32	-32	N/A
12/31/2022	N/A	-52	-44	-44	N/A
9/30/2022	N/A	-70	-53	-53	N/A
6/30/2022	N/A	-83	-63	-63	N/A
3/31/2022	N/A	-88	-66	-65	N/A
12/31/2021	N/A	-90	-63	-63	N/A
9/30/2021	N/A	-87	-62	-62	N/A
6/30/2021	N/A	-87	-57	-57	N/A
3/31/2021	N/A	-83	-54	-54	N/A
12/31/2020	N/A	-77	-51	-51	N/A
9/30/2020	N/A	-69	-49	-48	N/A
6/30/2020	N/A	-57	-45	-45	N/A
3/31/2020	N/A	-48	-37	-37	N/A
12/31/2019	N/A	-37	N/A	-33	N/A
9/30/2019	N/A	-28	N/A	-26	N/A
6/30/2019	N/A	-21	N/A	-19	N/A
3/31/2019	N/A	-15	N/A	-16	N/A
12/31/2018	N/A	-12	N/A	-12	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: QNCX önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: QNCX önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: QNCX önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: QNCX şirketinin gelirinin (yıllık 53% ) US pazarından (yıllık 11.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: QNCX şirketinin gelirinin (yıllık 53% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: QNCX 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/22 05:24
Gün Sonu Hisse Fiyatı	2026/05/22 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Quince Therapeutics, Inc. 9 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Tazeen Ahmad	BofA Global Research
Kumaraguru Raja	Brookline Capital Markets
Sumant Satchidanand Kulkarni	Canaccord Genuity

Quince Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Forecast to breakeven in 2028

Price target decreased by 33% to US$5.00

Forecast to breakeven in 2028

Price target decreased by 19% to US$7.25

No longer forecast to breakeven

Price target increased by 56% to US$12.00

Recent updates

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

Quince Therapeutics, Inc. (NasdaqGS:QNCX) acquired OrphAI Therapeutics Inc for $80.9 million.

Quince Therapeutics, Inc., Annual General Meeting, Jun 11, 2026

Quince Therapeutics, Inc. announced delayed annual 10-K filing

Quince Therapeutics, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Requirements

Insufficient new directors

Forecast to breakeven in 2028

Quince Therapeutics, Inc. Announces Resignation of Board of Directors Members, Effective January 30, 2026

Price target decreased by 33% to US$5.00

New minor risk - Profitability

New minor risk - Market cap size

Quince Therapeutics, Inc. Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia

New major risk - Share price stability

Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly?

Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential

Insider recently sold US$174k worth of stock

Forecast to breakeven in 2028

Quince Therapeutics, Inc. Announces Last Patient Last Visit in Phase 3 Neat Clinical Trial in Patients with Ataxia-Telangiectasia

New minor risk - Share price stability

Quince Therapeutics, Inc. Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics, Inc. Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia At 54Th Child Neurology Society Annual Meeting

Is Quince Therapeutics (NASDAQ:QNCX) Using Too Much Debt?

Quince Therapeutics, Inc. Announces the Publication of an Advanced Population Pharmacokinetic (PK) Modeling Study of Pediatric Patients with Ataxia-Telangiectasia and Healthy Adults Treated with Its Phase 3 Lead Asset, eDSP

New major risk - Financial position

New minor risk - Shareholder dilution

Quince Therapeutics, Inc. Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board

Quince Therapeutics, Inc.(NasdaqGS:QNCX) dropped from Russell Microcap Value Index

New minor risk - Share price stability

Quince Therapeutics, Inc. announced that it has received $11.488305 million in funding from ADAR1 Capital Management, LLC, Nantahala Capital Management, LLC

Quince Therapeutics, Inc. announced that it expects to receive $11.490305 million in funding from ADAR1 Capital Management, LLC, Nantahala Capital Management, LLC and other investors

Quince Therapeutics, Inc. Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics, Inc., Annual General Meeting, Jun 04, 2025

Price target decreased by 19% to US$7.25

No longer forecast to breakeven

Quince Therapeutics, Inc. Provides Update on Pivotal Phase 3 Neat Clinical Trial

Quince Therapeutics, Inc. Announces Frontiers in Neurology Publication of Long-Term Safety of EryDex in Pediatric Patients with Ataxia-Telangiectasia

Quince Therapeutics, Inc. Appoints Dr. William Whitehouse to Scientific Advisory Board

Quince Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

New minor risk - Shareholder dilution

Quince Therapeutics Presents Safety Data from Prior Phase 3 Attest Clinical Trial At 53rd Child Neurology Society Annual Meeting

New minor risk - Profitability

CEO, Chief Medical Officer & Director recently bought US$107k worth of stock

Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex

Quince Therapeutics, Inc. Announces the Online Publication of Data in the Lancet Neurology from Its Phase 3 Attest Clinical Trial Data Evaluating Erydex for the Treatment of Ataxia-Telangiectasia (A-T)

Quince Therapeutics, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Quince Therapeutics Receives Written Notice from Nasdaq Regarding Minimum Bid Price Requirement

Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System

Quince Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Quince Therapeutics, Inc. Launches Scientific Advisory Board

Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors

CEO & Director exercised options to buy US$336k worth of stock.

Independent Chairman of the board recently bought US$58k worth of stock

Quince Therapeutics Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer

Insufficient new directors

New minor risk - Shareholder dilution

Quince Therapeutics, Inc. Appoints Luca Benatti as Director

Quince Therapeutics, Inc. (NasdaqGS:QNCX) acquired EryDel S.p.A. for approximately $510 million.

Quince Therapeutics, Inc. Announces That U.S. Food and Drug Administration Lifts the Partial Clinical Hold on Erydel S.P. A's Investigational New Drug (Ind) Application for Its Lead Phase 3 Asset, Erydex

Quince Therapeutics Appoints Charles S. Ryan as President

Independent Chairman of the board recently bought US$108k worth of stock

Quince Therapeutics, Inc. Announces the Departure of Karen Smith as Chief Medical Officer, Effective September 1, 2023

CEO, President & Director recently bought US$99k worth of stock

New minor risk - Share price stability

Quince Therapeutics, Inc. (NasdaqGS:QNCX) agreed to acquire EryDel S.p.A. for approximately $490 million.

Biomed Industries, Inc. submitted a proposal to acquire Quince Therapeutics, Inc. (NasdaqGS:QNCX) for $10.5 million.

Price target increased by 56% to US$12.00

Quince Therapeutics Gets an Initial Compliance Period of 180 Calendar Days to Regain Compliance with the Minimum Bid Price Requirement